Pharma and Biotech
| China NDA Acceptance-Savolitinib in Gastric Cancer | 30-Dec-2025 | ShareCast |
| Blocklisting Six Monthly Return | 29-Dec-2025 | ShareCast |
| NDA Acceptance in China for Fanregratinib | 29-Dec-2025 | ShareCast |
| Hutchmed launches development programme for next... | 17-Dec-2025 | ShareCast |
| Hutchmed medicines get renewed, new reimbursemen... | 08-Dec-2025 | ShareCast |
| Vesting of awards under Long Term Incentive Plan | 16-Mar-2026 | 08:30 | RNS |
| Vesting of awards under Long Term Incentive Plan | 16-Mar-2026 | 08:30 | RNS |
| Vesting of awards under Long Term Incentive Plan | 11-Mar-2026 | 08:30 | RNS |
| Vesting of awards under Long Term Incentive Plan | 11-Mar-2026 | 08:30 | RNS |
| Update on Licensed Oncology Product in China | 09-Mar-2026 | 09:30 | RNS |
| Chinese medicine firm employs Cambridge Universi... | 23-Dec-2009 | Guardian |
| Joint venture offers food for growth | 09-Oct-2009 | The Scotsman |
| Chi-Med unveils maiden profit | 31-Jul-2009 | The Scotsman |
| Chi-Med happy with drug tests | 14-Jul-2009 | The Scotsman |
| 'Watershed' year depends on US drugs trial says ... | 17-Mar-2009 | The Scotsman |
| Questor: Hutchison China Meditech | 03-Jul-2007 | Telegraph |
| The Week Ahead: Wolseley investors seek calm ami... | 19-Mar-2007 | The Independent |
| The Investment Column: Hutchison China MediTech | 21-Nov-2006 | The Independent |
| Shares That Sound Good | 02-Jun-2006 | Motley Fool UK |
No recent information was found.
| Currency | UK Pounds |
| Share Price | 222.00p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 286.00 |
| 52 Week Low | 189.00 |
| Volume | 1,926 |
| Shares Issued | 872.33m |
| Market Cap | £1,936.57m |
| Beta | 0.01 |
| RiskGrade | 226 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 10:26 | 300 @ 220.92p |
| 10:26 | 471 @ 220.92p |
| 10:17 | 700 @ 220.92p |
| 09:36 | 455 @ 220.81p |
You are here: research